Treatment of pharyngeal non-Hodgkin lymphoma in a patient with Wiskott-Aldrich syndrome

Paola Coccia; Stefano Mastrangelo; Antonio Ruggiero; Maria Scalzone; Angelo Rosolen; Palma Maurizi; Riccardo Riccardi

doi:10.1002/pbc.23393

Treatment of pharyngeal non-Hodgkin lymphoma in a patient with Wiskott-Aldrich syndrome

Paola Coccia, Stefano Mastrangelo, Antonio Ruggiero, Maria Scalzone, Angelo Rosolen, Palma Maurizi, Riccardo Riccardi

Azienda Ospedaliera di Padova

Risultato della ricerca: Contributo in rivista › Articolo in rivista

8 Citazioni (Scopus)

Abstract

Wiskott-Aldrich syndrome (WAS) is characterized by primary immunodeficiency, thrombocytopenia and eczema. Patients with WAS have an increased risk to develop tumors. Non-Hodgkin lymphoma (NHL) represents the most common malignancy occurring in WAS-affected patients, diffuse-large-B-cell lymphoma is the most frequently encountered variant. We describe a case of a patient with WAS and NHL in the pharynx, an atypical tumor site presentation. The patient was successfully treated with a reduced dose chemotherapy regimen plus anti-CD20 monoclonal antibody. He is in complete remission 3 years from the start of treatment. Pediatr Blood Cancer 2012;59:318-319. © 2011 Wiley Periodicals, Inc.

Lingua originale	English
pagine (da-a)	318-319
Numero di pagine	2
Rivista	PEDIATRIC BLOOD & CANCER
Volume	59
DOI	https://doi.org/10.1002/pbc.23393
Stato di pubblicazione	Pubblicato - 2012

Keywords

Wiscott-Aldrich syndrome
pharyngeal non Hodgkin Lymphoma

OSS delle Nazioni Unite

Questo processo contribuisce al raggiungimento dei seguenti obiettivi di sviluppo sostenibile

Accesso al documento

10.1002/pbc.23393

Altri file e collegamenti

Link a IRIS PubliCatt

Cita questo

@article{df48edcd9f994e21a859fc6211aed9ec,

title = "Treatment of pharyngeal non-Hodgkin lymphoma in a patient with Wiskott-Aldrich syndrome",

abstract = "Wiskott-Aldrich syndrome (WAS) is characterized by primary immunodeficiency, thrombocytopenia and eczema. Patients with WAS have an increased risk to develop tumors. Non-Hodgkin lymphoma (NHL) represents the most common malignancy occurring in WAS-affected patients, diffuse-large-B-cell lymphoma is the most frequently encountered variant. We describe a case of a patient with WAS and NHL in the pharynx, an atypical tumor site presentation. The patient was successfully treated with a reduced dose chemotherapy regimen plus anti-CD20 monoclonal antibody. He is in complete remission 3 years from the start of treatment. Pediatr Blood Cancer 2012;59:318-319. {\textcopyright} 2011 Wiley Periodicals, Inc.",

keywords = "Wiscott-Aldrich syndrome, pharyngeal non Hodgkin Lymphoma, Wiscott-Aldrich syndrome, pharyngeal non Hodgkin Lymphoma",

author = "Paola Coccia and Stefano Mastrangelo and Antonio Ruggiero and Maria Scalzone and Angelo Rosolen and Palma Maurizi and Riccardo Riccardi",

year = "2012",

doi = "10.1002/pbc.23393",

language = "English",

volume = "59",

pages = "318--319",

journal = "PEDIATRIC BLOOD & CANCER",

issn = "1545-5009",

publisher = "Wiley Liss:111 River Street:Hoboken, NY 07030:(201)748-6000, (212)850-6645, EMAIL: [email protected], INTERNET: http://www.wiley.co.uk, Fax: (201)748-6088",

}

TY - JOUR

T1 - Treatment of pharyngeal non-Hodgkin lymphoma in a patient with Wiskott-Aldrich syndrome

AU - Coccia, Paola

AU - Mastrangelo, Stefano

AU - Ruggiero, Antonio

AU - Scalzone, Maria

AU - Rosolen, Angelo

AU - Maurizi, Palma

AU - Riccardi, Riccardo

PY - 2012

Y1 - 2012

N2 - Wiskott-Aldrich syndrome (WAS) is characterized by primary immunodeficiency, thrombocytopenia and eczema. Patients with WAS have an increased risk to develop tumors. Non-Hodgkin lymphoma (NHL) represents the most common malignancy occurring in WAS-affected patients, diffuse-large-B-cell lymphoma is the most frequently encountered variant. We describe a case of a patient with WAS and NHL in the pharynx, an atypical tumor site presentation. The patient was successfully treated with a reduced dose chemotherapy regimen plus anti-CD20 monoclonal antibody. He is in complete remission 3 years from the start of treatment. Pediatr Blood Cancer 2012;59:318-319. © 2011 Wiley Periodicals, Inc.

AB - Wiskott-Aldrich syndrome (WAS) is characterized by primary immunodeficiency, thrombocytopenia and eczema. Patients with WAS have an increased risk to develop tumors. Non-Hodgkin lymphoma (NHL) represents the most common malignancy occurring in WAS-affected patients, diffuse-large-B-cell lymphoma is the most frequently encountered variant. We describe a case of a patient with WAS and NHL in the pharynx, an atypical tumor site presentation. The patient was successfully treated with a reduced dose chemotherapy regimen plus anti-CD20 monoclonal antibody. He is in complete remission 3 years from the start of treatment. Pediatr Blood Cancer 2012;59:318-319. © 2011 Wiley Periodicals, Inc.

KW - Wiscott-Aldrich syndrome

KW - pharyngeal non Hodgkin Lymphoma

KW - Wiscott-Aldrich syndrome

KW - pharyngeal non Hodgkin Lymphoma

UR - http://hdl.handle.net/10807/23225

U2 - 10.1002/pbc.23393

DO - 10.1002/pbc.23393

M3 - Article

SN - 1545-5009

VL - 59

SP - 318

EP - 319

JO - PEDIATRIC BLOOD & CANCER

JF - PEDIATRIC BLOOD & CANCER

ER -

Treatment of pharyngeal non-Hodgkin lymphoma in a patient with Wiskott-Aldrich syndrome

Abstract

Keywords

OSS delle Nazioni Unite

Accesso al documento

Altri file e collegamenti

Fingerprint

Cita questo